Figure 3
Influence of cirrhosis grade on cytokine levels over the course of therapy. (a) Heatmap of median fold change of soluble marker levels in plasma compared to healthy donors for all measured cytokines in CHC patients with cirrhosis classified as Child Pugh A (Child A) or Child Pugh B (Child B). (b) Evolution of protein concentration (median ± IQR) in CHC patients over the course of treatment. Dotted lines and shaded area represent the median and 95% confidence interval of the median for healthy donors. Crosses and stars indicate significant difference between Child Pugh A and B groups overall and for each timepoint, respectively. ††p < 0.01; *p < 0.05; **p < 0.01. (c) Comparison between healthy donors (HD) and CHC patients with cirrhosis. BL: baseline; W4: week 4; EOT: end of treatment; FU: follow-up. (d) Spearman correlations between follow-up plasma concentration of sCD163 and different indicators of liver health. Dotted blue lines indicate 95% confidence intervals.
